URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1,cannabinoid receptor type 2,and transient receptor potential vanilloid 1 channels
Restricted accessResearch articleFirst published online July, 2021
URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1,cannabinoid receptor type 2,and transient receptor potential vanilloid 1 channels
Methamphetamine is an addictive stimulant that possesses toxicity in the brain when taken repeatedly or at higher doses. Methamphetamine neurotoxicity is associated with numerous forms of mental impairment, including depression and anxiety. Evidence has also demonstrated that the endocannabinoid system is involved in the regulation of anxiety and depression.
Aims:
This study was designed to determine the involvement of the endocannabinoid system in anxiety- and depression-related behaviors in methamphetamine-withdrawal male NMRI mice.
Methods:
The elevated plus maze and forced swim test were used to assess the level of anxiety and depression.
Results:
We found that methamphetamine (30 mg/kg, intraperitoneal) evoked depressive- and anxiogenic-like effects at 3 days post-administration. Injection of URB597 (5–10 ng/mouse, intracerebroventricular), 10 min before the test, prevented the emotional deficits induced by methamphetamine withdrawal. Moreover, the cannabinoid receptor type 1 antagonist AM251 (1 μg/mouse) or cannabinoid receptor type 2 antagonist AM630 (5 and 10 μg/mouse) suppressed the antidepressant activity in the methamphetamine-withdrawal mice treated with URB597. The transient receptor potential vanilloid 1 antagonist capsazepine (25 μg/mouse) prevented while capsazepine (100 μg/mouse) potentiated the antidepressant efficacy in the methamphetamine-withdrawal mice treated with URB597. The higher dose of AM630 and two higher doses of capsazepine had antidepressant efficacy, by themselves. Furthermore, capsazepine (50 μg/mouse) increased locomotion in the methamphetamine-withdrawal mice treated with URB597.
Conclusions:
The results suggest that URB597 has a potential for preventing methamphetamine withdrawal-evoked anxiety and depression. Cannabinoid type 1 receptors, cannabinoid type 2 receptors and transient receptor potential vanilloid 1 differently affect depression-related behaviors in methamphetamine-withdrawal mice treated with URB597.
AlijanpourSKhakpaiFEbrahimi-GhiriM, et al. (2019) Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice. Biomed Pharmacother109: 589–594.
2.
BortolatoMMangieriRAFuJ, et al. (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry62: 1103–1110.
3.
BrackinsTBrahmNCKissackJC (2011) Treatments for methamphetamine abuse: A literature review for the clinician. J Pharm Pract24: 541–550.
4.
CadetJLJayanthiSDengX (2003) Speed kills: Cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J17: 1775–1788.
5.
de LagoEde MiguelRLastres-BeckerI, et al. (2004) Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence. Brain Res1007: 152–159.
6.
DuanTGuNWangY, et al. (2017) Fatty acid amide hydrolase inhibitors produce rapid anti-anxiety responses through amygdala long-term depression in male rodents. J Psychiatry Neurosci42: 230–241.
7.
Ebrahimi-GhiriMShahiniFKhakpaiF, et al. (2019a) Antinociceptive and antidepressive efficacies of the combined ineffective doses of S-ketamine and URB597. Naunyn Schmiedebergs Arch Pharmacol392: 1393–1400.
8.
Ebrahimi-GhiriMNasehiMZarrindastM-R (2019b) Anxiolytic and antidepressant effects of ACPA and harmaline co-treatment. Behav Brain Res364: 296–302.
9.
FalenskiKWThorpeAJSchlosburgJE, et al. (2010) FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology35: 1775–1787.
10.
FarranB (2017) An update on the physiological and therapeutic relevance of GPCR oligomers. Pharmacol Res117: 303–327.
11.
FegleyDGaetaniSDurantiA, et al. (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther313: 352–358.
12.
Garcia-GutierrezMSManzanaresJ (2011) Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. J Psychopharmacol25: 111–120.
13.
Garcia-GutierrezMSGarcia-BuenoBZoppiS, et al. (2012) Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors. Br J Pharmacol165: 951–964.
14.
Garcia-GutierrezMSPerez-OrtizJMGutierrez-AdanA, et al. (2010) Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol160: 1773–1784.
15.
GiuffridaAParsonsLHKerrTM, et al. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci2: 358–363.
16.
GobbiGBambicoFRMangieriR, et al. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A102: 18620–18625.
17.
GuimaraesFSChiarettiTMGraeffFG, et al. (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology100: 558–559.
18.
GutierrezAWilliamsMTVorheesC V (2018) A single high dose of methamphetamine reduces monoamines and impairs egocentric and allocentric learning and memory in adult male rats. Neurotox Res33: 671–680.
19.
HakimizadehEOryanSMoghaddamAH, et al. (2012) Endocannabinoid system and TRPV1 receptors in the dorsal hippocampus of the rats modulate anxiety-like behaviors. Iran J Basic Med Sci15: 795–802.
20.
HallerJBakosNSzirmayM, et al. (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Euro J Neurosci16: 1395–1398.
21.
HallerJBarnaIBarsvariB, et al. (2009) Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology204: 607–616.
22.
HayGLBaraczSJEverettNA, et al. (2018) Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. J Psychopharmacol32: 1369–1378.
23.
HayaseT (2011) Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors. BMC Pharmacol11: 6.
24.
HillMNMcLaughlinRJMorrishAC, et al. (2009) Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology34: 2733–2745.
25.
HowlettACBarthFBonnerTI, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev54: 161–202.
26.
IversenL (2003) Cannabis and the brain. Brain126: 1252–1270.
27.
KhakpaiFEbrahimi-GhiriMAlijanpourS, et al. (2019) Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system. Biomed Pharmacother112: 108717.
28.
KishSJFitzmauricePSBoileauI, et al. (2009) Brain serotonin transporter in human methamphetamine users. Psychopharmacology202: 649–661.
29.
KitanakaJKitanakaNScott HallF, et al. (2016) Brain histamine N-methyltransferase as a possible target of treatment for methamphetamine overdose. Drug Target Insights10: 1–7.
30.
KomakiAHashemi-FirouziNShojaeiS, et al. (2015) Study the effect of endocannabinoid system on rat behavior in elevated plus-maze. Basic Clin Neurosci6: 147–153.
31.
Kruk-SlomkaMMichalakABialaG (2015) Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: Mechanism of action and possible interactions with cholinergic system. Behav Brain Res284: 24–36.
32.
LondonEDSimonSLBermanSM, et al. (2004) Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry61: 73–84.
33.
MalinowskaBKwolekGGothertM (2001) Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol364: 562–569.
34.
MannaSSSUmatheSN (2012) A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine. Euro J Pharmacol685: 81–90.
35.
MarcoEMPerez-AlvarezLBorcelE, et al. (2004) Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol15: 21–27.
36.
MarsicanoGLutzB (2006) Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest29: 27–46.
37.
MelisMPistisMPerraS, et al. (2004) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci24: 53–62.
38.
MorMRivaraSLodolaA, et al. (2004) Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem47: 4998–5008.
39.
MoutonMHarveyBHCockeranM, et al. (2016) The long-term effects of methamphetamine exposure during pre-adolescence on depressive-like behaviour in a genetic animal model of depression. Metab Brain Dis31: 63–74.
40.
NaderJRapinoCGennequinB, et al. (2014) Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. Neuropharmacology87: 214–221.
41.
NasehiMImaniEEbrahimi-GhiriM, et al. (2020) Effects of precondition alpha2-adrenoceptor agents on memory- and anxiety-related processes in the transient cerebral ischemic rats. Naunyn Schmiedebergs Arch Pharmacol393: 315–324.
42.
NawataYYamaguchiTFukumoriR, et al. (2019) Inhibition of monoacylglycerol lipase reduces the reinstatement of methamphetamine-seeking and anxiety-like behaviors in methamphetamine self-administered rats. Int J Neuropsychopharmacol22: 165–172.
43.
NguyenTThomasBFZhangY (2019) Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: Current approaches for therapeutics development. Curr Top Med Chem19: 1418–1435.
44.
OnaiviESIshiguroHGongJ-P, et al. (2008a) Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: From mice to human subjects. PLoS One3: e1640.
45.
OnaiviESIshiguroHGongJ-P, et al. (2008b) Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci1139: 434–449.
46.
PatelSHillardCJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther318: 304–311.
47.
PaxinosGFranklinK (2001) The Mouse Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press.
48.
PiomelliDTarziaGDurantiA, et al. (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev12: 21–38.
49.
PoleszakEWoskoSSlawinskaK, et al. (2020) Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice. Pharmacol Biochem Behav188: 172833.
50.
PrakashMDTangalakisKAntonipillaiJ, et al. (2017) Methamphetamine: Effects on the brain, gut and immune system. Pharmacol Res120: 60–67.
51.
RawsonRA (2013) Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use. J Food Drug Anal21: S77–S81.
52.
ReyAAPurrioMViverosM-P, et al. (2012) Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology37: 2624–2634.
53.
RibeiroAFerraz-de-PaulaVPinheiroML, et al. (2009) Dose-response effects of systemic anandamide administration in mice sequentially submitted to the open field and elevated plus-maze tests. Braz J Med Biol Res42: 556–560.
54.
RicaurteGASchusterCRSeidenLS (1980) Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study. Brain Res193: 153–163.
55.
RuQXiongQZhouM, et al. (2019) Withdrawal from chronic treatment with methamphetamine induces anxiety and depression-like behavior in mice. Psychiatry Res271: 476–483.
56.
RubinoTRealiniNCastiglioniC, et al. (2008) Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex18: 1292–1301.
57.
SeidenLSSabolKERicaurteGA (1993) Amphetamine: Effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol33: 639–677.
58.
ShearmanLPRoskoKMFleischerR, et al. (2003) Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol14: 573–582.
59.
ShoblockJRSullivanEBMaisonneuveIM, et al. (2003) Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology165: 359–369.
60.
Silva CarlosDNevesAFDiasAI, et al. (2014) A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice. Neurotox Res25: 295–304.
61.
Stampanoni BassiMGilioLMaffeiP, et al. (2018) Exploiting the multifaceted effects of cannabinoids on mood to boost their therapeutic use against anxiety and depression. Front Mol Neurosci11: 1–11.
TothABlumbergPMBoczanJ (2009) Anandamide and the vanilloid receptor (TRPV1). Vitam Horm81: 389–419.
64.
UmatheSNMannaSSSJainNS (2011) Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. Behav Brain Res223: 125–134.
65.
Van SickleMDDuncanMKingsleyPJ, et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science310: 329–332.
66.
VinodKYXieSPsychoyosD, et al. (2012) Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats. PLoS One7: e36743.
67.
VolkowNDHampsonAJBalerRD (2017) Don’t worry, be happy: Endocannabinoids and cannabis at the intersection of stress and reward. Annu Rev Pharmacol Toxicol57: 285–308.
YinAQWangFZhangX (2019) Integrating endocannabinoid signaling in the regulation of anxiety and depression. Acta Pharmacol Sin40: 336–341.
70.
YouI-JJungY-HKimM-J, et al. (2012) Alterations in the emotional and memory behavioral phenotypes of transient receptor potential vanilloid type 1-deficient mice are mediated by changes in expression of 5-HT(1)A, GABA(A), and NMDA receptors. Neuropharmacology62: 1034–1043.
71.
ZhangLXiongW (2009) Modulation of the Cys-loop ligand-gated ion channels by fatty acid and cannabinoids. Vitam Horm81: 315–335.
